1	Infants and young children generate more durable antibody responses to SARS-CoV-2				
2	infection than adults				
3	Devyani Joshi ^{1,2,3} , Lindsay E. Nyhoff ^{1,2,3} , Veronika I. Zarnitsyna ⁴ , Alberto Moreno ^{1,2,5} , Kelly				
4	Manning ^{1,2,5} , Susanne Linderman ^{2,4} , Allison R Burrell ^{6,7} , Kathy Stephens ³ , Carson Norwood ^{2,3,8}				
5	Grace Mantus ^{2,3,8} , Rafi Ahmed ^{2,4} , Evan J. Anderson ^{1,3,8} , Mary A. Staat ^{6,9} , Mehul S. Suthar ^{1,2,3,4,5} ,				
6	and Jens Wrammert ^{1,2,3*}				
7					
8	¹ Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory				
9	University, Atlanta, Georgia, USA				
10	² Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA				
11	³ Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta,				
12	Georgia, USA				
13	⁴ Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA				
14	⁵ Emory National Primate Research Center, Atlanta, Georgia, USA				
15	⁶ Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati,				
16	Ohio, USA				
17	⁷ Department of Environmental and Public Health Sciences, Division of Epidemiology,				
18	University of Cincinnati College of Medicine, Cincinnati, OH, USA				
19	⁸ Department of Medicine, Emory University, School of Medicine, Atlanta, Georgia, USA				
20	⁹ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA				
21					
22	*Correspondence:				
23	Jens Wrammert, PhD				

- 24 Department of Pediatrics
- 25 Division for Infectious Disease
- 26 Emory Vaccine Center
- 27 School of Medicine
- 28 Emory University
- 29 email: jwramme@emory.edu
- 30 Phone: 404-778-3265
- 31

32 Abstract

33 Since the emergence of SARS-CoV-2, research has shown that adult patients mount broad and 34 durable immune responses to infection. However, response to infection remains poorly studied in 35 infants/young children. In this study, we evaluated humoral responses to SARS-CoV-2 in 23 36 infants/young children before and after infection. We found that antibody responses to SARS-37 CoV-2 spike antigens peaked approximately 30 days after infection and were maintained up to 38 500 days with little apparent decay. While the magnitude of humoral responses was similar to an 39 adult cohort recovered from mild/moderate COVID-19, both binding and neutralization titers to 40 WT SARS-CoV-2 were more durable in infants/young children, with Spike and RBD IgG 41 antibody half-life nearly 4X as long as in adults. The functional breadth of adult and 42 infant/young children SARS-CoV-2 responses were comparable, with similar reactivity against 43 panel of recent and previously circulating viral variants. Notably, IgG subtype analysis revealed 44 that while IgG1 formed the majority of both adults' and infants/young children's response, IgG3 45 was more common in adults and IgG2 in infants/young children. These findings raise important 46 questions regarding differential regulation of humoral immunity in infants/young children and 47 adults and could have broad implications for the timing of vaccination and booster strategies in 48 this age group.

49

50 Keywords

51 Infants, Antibody Response, Durability, SARS-CoV-2, Variants

52

53

55 Introduction

56 More than three years since the SARS-CoV-2 virus was first detected in humans, it continues to 57 cause severe morbidity and mortality worldwide (1, 2). Durable immune responses against 58 SARS-CoV-2 are crucial for prevention of severe disease and for protection against the 59 continuously emerging viral variants (3). The breadth and durability of the immune response has 60 been extensively studied following infection, as well as after primary and booster series of 61 vaccination, in both adults and older children (4-10). However, the immune response following 62 SARS-CoV-2 infection in infants and very young children remains poorly understood. 63 Although approximately one fourth of infants infected with SARS-CoV-2 are asymptomatic and 64 there are few reported deaths, severe COVID-19 is more common in young infants as compared 65 to older children (11-13). The immune system of infants starts to develop in the first few months 66 after delivery (14). Very little is known about how the immature immune system of an infant or 67 young child reacts to SARS-CoV-2 infection, and how the infection in those children in turn 68 impacts the development of the immune system. Even less is known about the durability of 69 immunity, given the difficulty of designing and executing multi-sample longitudinal studies in 70 these age groups. Thus, evaluation of the initial magnitude and the long-term durability of 71 infection-induced immune responses in infants/young children is critical. Moreover, a deeper 72 understanding of the breadth of humoral immune responses against continuously emerging viral 73 variants in infants/young children is vital for optimizing the timing of current vaccination 74 strategies in this age group (15, 16).

In this study, we present findings from the IMPRINT study; a prospective, longitudinal birth cohort of influenza and SARS-CoV-2 infection and vaccination in early life conducted at Cincinnati Children's Hospital Medical Center. IMPRINT participants provide weekly parent-

78 administered mid-turbinate nasal swabs, allowing for real-time identification of SARS-CoV-2 79 infected infants and young children. Multiple blood samples were obtained from these infants 80 and children over a period of up to 500 days after their initial SARS-CoV-2 positive swab. This 81 pediatric cohort was then compared to an adult cohort on which we have previously reported, 82 which collected blood samples from patients with PCR confirmed SARS-CoV-2 infection that 83 were followed for up to 350 days post infection (5). Herein we report that while the initial 84 magnitude of the SARS-CoV-2 specific antibody response in adults and infants/young children 85 was comparable, the titers in our infant cohort were maintained over the study period, while in 86 adults the titers declined with a half-life of 180 days (as previously reported by us and others) (5, 87 17, 18). Despite this major difference in terms of durability of humoral immunity, the functional 88 breadth of these responses was similar in adults and infants/young children, since the breadth of 89 reactivity against a panel of viral variants was essentially identical between these groups. Our 90 findings show significant differences in the maintenance of antibody responses in adults and 91 infants/young children and suggest that booster vaccination scheduling strategies in 92 infants/young children may need further evaluation. 93 94 **Results** 95 96 **Study cohort** 97 We included a total of 23 infants/young children and 19 adults in the study cohort. The 98 infants/young children, recruited at Cincinnati Children's Hospital, were followed since birth and 99 up to 500 days after their first positive PCR result for SARS-CoV-2. The COVID-19 confirmed 100 adult patients were previously enrolled in our longitudinal study of COVID-19 immune

101	durability (5), and followed for up to 350 days post-infection. Of the adults, a majority (84 %)				
102	were non-hospitalized, and none had severe symptoms. Infants/young children were infected				
103	during April 2020 – January 2022, and adults were infected during March – April 2020				
104	(Supplementary Figure 1) (19, 20). The demographics and baseline characteristics of these				
105	cohorts are described in Table 1. The infant cohort was 57 % females and 43 % males and				
106	between 40 and 1441 days old (median age, 249 days). The adult cohort was 53 % females and				
107	47 % males and between 20 and 77 years (median, 54 years).				
108					
109	Durable antibody responses in infants/young children after SARS-CoV-2 infection.				
110	The magnitude and durability of antibody responses after SARS-CoV-2 infection have not been				
111	carefully studied in infants/young children. Here we evaluated the longitudinal plasma antibody				
112	responses against several SARS-CoV-2 antigens (Spike, RBD and NTD) pre-infection, during				
113	acute infection, and following recovery in 23 SARS-CoV-2 infected infants and young children				
114	using the Meso Scale Discovery electrochemiluminescence multiplex assay (MSD). All				
115	infants/young children exhibited measurable IgG and IgA responses against Spike, RBD, and				
116	NTD after infection, while IgM responses were negligible not only prior to infection, but also at				
117	acute infection and convalescence stages in most individuals (data not shown). Pre-infection				
118	levels of IgG and IgA against SARS-CoV-2 spike (Figure 1A and D), spike receptor binding				
119	domain (RBD) (Figure 1B and E), and spike N-terminal domain (NTD) (Figure 1C and F)				
120	were below the limit of detection, excluding an impact by maternal antibodies. The SARS-CoV-				
121	2-specific IgG and IgA levels increased rapidly during acute infection, with subjects generating				
122	detectable antibody responses as early as day four and peaking approximately 30 days post-				

- 123 infection. The antibody titers were maintained following recovery for up to 500 days after the
- 124 positive PCR test with little apparent decay.
- 125

126 SARS-CoV-2 infection results in increased antibody titers against the epidemic

127 coronaviruses MERS-CoV and SARS-CoV-1 in infants/young children

- 128 We further evaluated the IgG antibody titers against the epidemic coronaviruses SARS-CoV-1
- and MERS-CoV spike protein. The IgG binding antibody titers against both SARS-CoV-1 and
- 130 MERS-CoV spike protein increased during the acute phase of SARS-CoV-2 infection. IgG titers
- 131 peaked approximately 30 days post-infection and were maintained with little to no apparent
- 132 decay for up to 500 days post infection. (Figure 2A). Given that none of the infants/young
- 133 children could have been exposed to these coronaviruses, the increase in the IgG antibodies most
- 134 likely represents cross-reactive antibodies directed to SARS-CoV-2 spike epitopes which are
- 135 largely conserved between SARS-CoV-1, MERS-CoV and SARS-CoV-2 (21). This shows a
- 136 heightened immunity to the epidemic coronaviruses upon SARS-CoV-2 infection in
- 137 infants/young children.
- 138

139 Pre-existing IgG antibody titers against the seasonal β-coronaviruses HKU1 and OC43

140 spike protein do not impact antibody responses after SARS-CoV-2 infection.

141 It has been postulated that pre-existing antibody responses against seasonal beta-coronaviruses

142 might impact the responses against SARS-CoV-2. Since we had access to pre-infection samples

- 143 for this cohort, we next evaluated the IgG binding antibody response to the common human
- 144 coronaviruses HKU1 and OC43 in the pre-infection, acute infection, and convalescent plasma
- samples from 23 SARS-CoV-2 infected infants/young children using the MSD assay. Overall,

146	IgG titers against the spike proteins of HKU1 and OC43 were largely unaffected by the SARS-
147	CoV-2 infection (Figure 2B). More importantly, post-infection titers against the SARS-CoV-2
148	spike protein showed no correlation to the baseline (pre-infection) titers against the HKU1 and
149	OC43 spike protein (Figure 2C) indicating that the level of pre-existing antibodies against
150	common human coronaviruses did not impact the anti-SARS-CoV-2 antibody response
151	following infection in infants and young children.
152	
153	Infants and young children show a more durable binding antibody response upon SARS-
154	CoV-2 infection as compared to adults.
155	An important aspect of serological immunity is the durability of protection induced by infection.
156	To compare how the durability of antibody responses in infants/young children may differ from
157	that in adults, we compared these results to a cohort of adult patients on which we have
158	previously reported (5). The IgG responses to SARS-CoV-2 spike, RBD and NTD in infants and
159	young children were found to show minimal to no decay over time, with an estimated half-life of
160	800 (95 % confidence interval [95 % CI] [222, ∞]), 775 (95 % CI [263, ∞]), and 828 (95 % CI
161	[299, ∞]) days respectively, as estimated by the exponential decay model (Figure 3A-C). In
162	contrast, IgG antibodies specific to SARS-CoV-2 spike, RBD and NTD in adults were found to
163	decay much faster, with an estimated half-life of 187 (95 % CI [141, 281]), 178 (95 % CI [134,
164	264]), and 204 (95 % CI [149, 323]) days, respectively (Figure 3E, 3F, and 3G). We also
165	calculated the antibody decay using the power law decay model, which assumes that decay rates
166	decrease over time (5). The half-lives estimated by the power law model at day 150 for IgG
167	antibodies binding to SARS-CoV-2 spike, RBD, and NTD in the infants/young children were
168	1964 (95 % CI [204, ∞]), 2986 (95 % CI [492, ∞]), and 14190 (95 % CI [192, ∞]) days,

respectively. The longer half-lives as estimated by the power law model indicate that the decay rate of the IgG antibodies declines over time, and that the concentration of the antibodies starts to stabilize. In the adults, the half-lives of the IgG antibodies binding to spike, RBD and NTD, as estimated by the power law model at day 150, were 405 (95 % CI [250, 915]), 356 (95 % CI [228, 738]), and 450 (95 % CI [268, 1128]) days respectively.

174 As we have reported earlier in adults (5), anti-nucleocapsid IgG antibodies were found to 175 decline more rapidly compared to antibodies to other SARS-CoV-2 antigens. Interestingly, we 176 observed a similar fast decay in infants/young children, with the decay rate not statistically 177 different between the two groups (p = 0.77 for the exponential decay model and p = 0.9 for the 178 power law decay model, the Wald test). The half-lives of IgG antibodies binding to nucleocapsid 179 protein in infants/young children as calculated by the exponential and power law models were 180 116 (95 % CI [80, 216]), and 139 (95 % CI [83, 388]) days respectively (Figure 3D). The half-181 lives of IgG antibodies binding to nucleocapsid protein in adults as calculated by the exponential 182 and power law models were 83 (95 % CI [73, 96]), and 116 (95 % CI [97, 144) days respectively 183 (Figure 3H). Taken together, these results suggest that infants and young children show a more 184 durable binding antibody response to spike protein antigens and comparable durability of binding 185 antibody response to nucleocapsid protein upon SARS-CoV-2 infection as compared to adults.

186

Infants/young children and adults show differences in IgG subclass distribution after SARS-CoV-2 infection.

189 To better understand the infection-induced humoral response in infants and young children and 190 to evaluate potential differences with the adult response, we next tested the anti-spike IgG 191 subclasses usage in a subset of samples representing early (30 – 140 days post infection) and late

192	(250 – 375 days post infection) time points following infection (Figure 4A). The IgG responses
193	can be further categorized into IgG1, IgG2, IgG3 and IgG4 antibody responses. Each of these
194	subclasses have unique properties and effector functions that are driven by the Fc portion of the
195	antibody molecule (22). Thus, we sought to characterize the IgG subclass usage of the SARS-
196	CoV-2 antibody response. IgG1 was found to be the most dominant subclass in both
197	infants/young children and adults, generating titers of $1 - 100 \ \mu\text{g/mL}$ in both infants/young
198	children and adults. However, we observed notable differences in the anti-spike IgG subclass
199	distribution. The second most prevalent IgG subclass in infants was IgG2, forming $1 - 10 \ \mu g/mL$
200	of the anti-Spike IgG response. In contrast, adults were significantly more likely to produce IgG3
201	(p=0.0294) (Figure 4B). These differences were most apparent at early time points, as the titers
202	in adults dropped over time and titers in infants/young children maintained, confirming the
203	higher durability of the antibody response in infants/young children.
204	

Infants/young children generate more durable neutralizing antibody response against WT SARS-CoV-2 as compared to adults.

207 We next evaluated early and late time points in infants and adults following infection to assess 208 the magnitude and durability of neutralizing antibody to WT (WA1\2020) SARS-CoV-2 strain 209 (Figure 5A). The neutralizing antibodies were measured using a live virus focus reduction 210 neutralization (FRNT) assay. Infants/young children and adults showed comparable neutralizing 211 antibody titers against WT SARS-CoV-2 at the early post-infection time point, with median 212 neutralizing antibody titers of 125 and 128 in infants/young children and adults, respectively. 213 73% of infants/young children and 68% of adults showed neutralizing antibody titer above the 214 limit of detection (> 20). In contrast, at the late time point infants/young children showed a

significantly higher neutralizing antibody response against WT SARS-CoV-2 as compared to the adults, with the median neutralizing antibody titers of 131 in infants/young children and 22 in adults (p = 0.0151). Furthermore, at the later time point 100% of infants/young children registered neutralizing antibody titer above the limit of detection as opposed to only 58% of adults.

Next, we assessed the relationship between anti-spike and anti-RBD antibody and neutralizing antibody level in both infants and adults (**Figure 5B**). The spike and RBD IgG levels were found to correlate significantly to the neutralizing antibody titer, at both early and late time points, in infants/young children and adults (p < 0.0001) alike. The strong correlation of anti-spike and anti-RBD titers with neutralization, combined with the observation of increased durability of said titers, provides more evidence that infants/young children can maintain both binding and neutralizing antibody titers for a much longer period as compared to adults.

227

228 The antibody breadth against VOCs is similar in infants/young children and adults.

229 To address potential functional differences in the antibody repertoire, we analyzed the ability to 230 bind and neutralize a panel of viral VOCs using early and late time point plasma samples from 231 infants/young children and adults. These analyses included the beta, delta, and omicron (BA.1) 232 variants. For the RBD IgG binding antibody response, infants/young children showed a 3-fold 233 reduction and adults showed a 4-fold reduction in binding to beta variant. Infants/young children 234 and adults showed a comparable 1 - 2-fold reduction in binding to delta variant. The reduction in 235 binding was more pronounced in case of Omicron (BA.1) variant with infants/young children 236 showing 17-fold reduction at early and 8-fold reduction at late time point, while adults showing 237 12-fold reduction at early and 9-fold reduction at late time point (Figure 6A). Similarly, for anti-

spike IgG titers, infants/young children and adults showed a 2-fold reduction in binding to beta
and 1 – 2-fold reduction in binding to delta variants. The reduction in binding was more evident
in case of Omicron (BA.1) variant. The infants/young children showed a 10-fold reduction in
binding at both early and late time points, while adults showed a 9-fold and 7-fold reduction in
banding at early and late time points respectively (Supplementary Figure 2).

243 Furthermore, both infants/young children and adults showed a significant reduction in 244 neutralizing ability against beta, delta and Omicron (BA.1) variants. The infants/young children 245 showed a 2-3-fold reduction in neutralization against beta and 1-fold reduction in neutralization 246 against delta variant. Adults showed a 2-5-fold reduction in neutralization against beta and 1-247 fold reduction in neutralization against delta variant. The reduction in neutralization was even 248 more evident in case of Omicron (BA.1) variant. Infants/young children showed 6-fold and 7-249 fold reduction, whereas adults showed 8-fold and 3-fold reduction in neutralization against 250 Omicron (BA.1) at early and late time points respectively (Figure 6B). Taken together, these 251 data suggest that the SARS-CoV-2 infected infants/young children and adults show a similar 252 breadth of antibody response against VOCs, with a significant reduction in the binding and 253 neutralizing ability against an Omicron (BA.1) variant.

254

255 Discussion

256

As SARS-CoV-2 establishes itself as an endemic infection, exposure in early childhood may become routine. Therefore, it is critical to evaluate the magnitude and durability of immunity following early life infection, which may help to predict whether early immunity is sufficient to prevent new infections and severe disease later in life. Additionally, comparison of the immune

261 response to infection in infants/young children to that of adults provides essential context for 262 effective scheduling of primary and booster vaccinations across all age groups in view of 263 continuously emerging viral variants. Our study of longitudinally sampled infants/young children 264 is uniquely suited to evaluate these factors. These donors were followed with weekly nasal swabs 265 and timely blood collections beginning soon after birth, which allowed us to identify both 266 symptomatic and asymptomatic respiratory infections and evaluate the immune response both 267 prior to SARS-CoV-2 infection and longitudinally after the first infection in early life. In 268 addition, our cohort of longitudinally followed, non-severe adult COVID-19 patients enables a 269 direct comparison of the infection-induced immune response in these age groups. To address the 270 question of the durability of immune responses following infection, we evaluated the half-life of 271 antibodies to SARS-CoV-2 antigens. The most striking finding of our study was that the 272 infants/young children generated a much more durable binding and neutralizing antibody 273 response as compared to adults following SARS-CoV-2 infection. In adults, the half-life of IgG 274 binding antibodies was in the range of 178-204 days as estimated by the exponential decay 275 model. This finding is in line with the range our group and others have reported in the past (5, 276 17, 18). It is well established that the loss of binding titers results in a coordinated loss of 277 neutralization titer (Figure 5A) (16, 23-25), most likely due to the strong correlation between 278 spike and RBD binding titers and neutralization (Figure 5B) (11, 26), indicating that fraction of 279 anti-spike/RBD IgG is able to block SARS-CoV-2 entry into cells. The relatively rapid decline in 280 binding and neutralization titers in adults is one factor that drives the recommended frequency of 281 vaccine boosters. Therefore, it is a valuable insight that infants/young children showed a much more durable antibody response with half-lives of 700 - 800 days, nearly four times that of 282 283 adults (Figure 3). Though the early and adult immune systems differ in a myriad of ways (27),

284 infants/young children were able to generate robust neutralization titers. Indeed, infants/young 285 children and adults produced neutralization titers comparable in magnitude early during the 286 response to infection. In contrast to the rapidly declining neutralization titers in adults, the 287 infants/young children did not exhibit significant reduction in neutralization titers at late time 288 points, highlighting the longer durability of immunity following infection in this age group. 289 These differences between infants/young children and adults could be due to different 290 immunological milieus during the induction of the responses during acute infection, which could 291 result in differences in the generation of long-lived plasma cells or be mediated by differences in 292 the ability of the infant and adult bone marrow to support the survival of long-lived SARS-CoV-293 2 specific plasma cells. The mechanistic explanation for our findings requires further study. 294 Notably, the striking differences in the durability of binding antibody to SARS-CoV-2 S antigens 295 is not observed in regard to anti-nucleocapsid IgG. Infants/young children and adults exhibit a 296 comparable rapid decline of anti-nucleocapsid IgG antibodies. This suggests that anti-spike, -297 RBD and -nucleocapsid humoral responses may be differentially regulated and implies that the 298 increased durability in infants/young children is not necessarily universal for every antigen. It is 299 possible that location, concentration, and/or availability of antigens differs during infection in 300 adults compared to infants/young children, and that exploring these differences may lead to 301 uncovering factors that could modulate durability of humoral immunity in adults. The spike 302 protein of SARS-CoV-2 is a critical target of mRNA vaccines (28, 29), and the higher durability 303 of spike-binding and neutralizing antibodies in infants/young children raise a possibility of 304 similar increased durability of the immune response to vaccination, which may further impact 305 booster scheduling in this age group. This cohort of donors, as well as peers who have not 306 experienced infection, will continue to be followed, allowing us to build on these results and

address important questions regarding durability of immune response to primary and booster
 series of vaccination in infection-experienced and naïve children. Overall, these findings provide
 important insight into the humoral immune response in very young children in a world in which
 childhood SARS-CoV-2 infection may become endemic.

311 Our study also observed variability in the IgG subclass usage in response to infection in 312 infants/young children as compared to adults. As we have shown previously in adults (30), we 313 observed a predominance IgG1 antibodies in both infants/young children and adults. Indeed, 314 while IgG1 formed the most dominant subclass, adults and children differed in their secondary 315 subtype, showing significant contribution of IgG2 in infants/young children and IgG3 in adults. 316 IgG2 is known to be associated with neutralization and non-inflammatory response, and is 317 known to reduce the detrimental effect of antibody-dependent enhancement (ADE), whereas 318 IgG1, IgG3, and IgG4 are associated with both neutralization and ADE effects (31, 32). The 319 higher contribution of IgG2 antibodies in infants/young children may contribute to less severe 320 disease and fewer deaths in this age group as compared to adults. While subclass differences 321 were subtle, these findings may provide important clues for how the immune response to 322 infection is regulated in adults and infants/young children, and continued investigation may have 323 broader implications for future vaccine development that could target a specific subclass of 324 antibodies.

Another relevant question is whether pre-existing immunity against the commonly circulating human coronaviruses (HKU1 and OC43) provides cross-protection against SARS-CoV-2 infection? Although cross-reactivity and/or cross-protection between SARS-CoV-2 and HCoVs has been reported (33-35), we found no evidence of a major impact of pre-existing seasonal HCoVs titers on the magnitude or quality of SARS-CoV-2 responses in infants/young

330	children. Since virtually all adults have experienced infection with common human				
331	coronaviruses and will therefore have pre-existing titers (5), the study of infants/young children				
332	provides a unique opportunity to assess responses to SARS-CoV-2 without pre-existing				
333	exposure. While this study could not measure protection, the pre-infection baseline titers of				
334	HCoVs' spike protein did not correlate with the SARS-CoV-2 spike convalescent IgG antibody				
335	titers, suggesting pre-existing antibody titers did not result in an increased humoral response to				
336	SARS-CoV-2. It is also evident from low to non-existent IgG and IgA titers against the SARS-				
337	CoV-2 antigens observed in the pre-infection samples in the infants/young children, suggesting				
338	that the SARS-CoV-2 infection and immune response is independent of the HCoVs' serostatus.				
339	This is in line with other studies done in older children and adults where the cross-protection by				
340	HCoVs has not been reported (36, 37). These important observations again highlight the need for				
341	vaccination against SARS-CoV-2 in infants/young children despite the pre-existing immunity				
342	against seasonal beta-coronaviruses. However, likely due to the high degree of spike protein				
343	conservation (21), we did find an increase in the IgG binding antibody titers against previous				
344	endemic coronaviruses, MERS-CoV and SARS-CoV-1 upon SARS-CoV-2 infection in				
345	infants/young children. This finding is consistent with other studies where SARS-CoV-1 titers				
346	were found to increase upon SARS-CoV-2 infection and mRNA vaccination in adults (5, 38).				
347	Taken together, these results may have implications for a broader strategy for vaccination				
348	targeting multiple human beta-coronaviruses.				
349	Despite the differences in durability, our study demonstrated a very similar breadth of				
350	antibody repertoire in infants/young children and adults against VOCs such as beta, delta, and				
351	omicron (BA.1). We found lower binding and neutralizing antibody titers against beta and delta				
352	variants as compared to the WT in both infants/young children and adults, with differences being				

353 most apparent in the beta variant. As expected, the largest differences were observed for the 354 omicron variant (BA.1). Prior SARS-CoV-2 infection in adults has shown to not confer cross-355 protection against the omicron variant (39, 40) in adults, an observation that impacted the 356 approval of the bivalent booster. However, this has not been fully characterized in infants/young 357 children. As observed in adults, we found a marked reduction in binding and neutralizing 358 antibody titers against omicron (BA.1) variant in infants/young children. This underscores the 359 potential of this VOC to evade the infection-induced immune response and cause re-infections in 360 infants/young children even in light of their improved antibody durability. Booster vaccination 361 increases responses to omicron in adults (41), and may rescue lower responses in infants/young 362 children and may be necessary to protect from continuously emerging viral variants. 363 SARS-CoV-2 remains a global public health threat even after years of devastating 364 disturbances and loss. To date, vaccination remains the best possible strategy in the fight against 365 COVID-19. Thus, development of the booster vaccines that target evolving viral variants and 366 optimum scheduling of vaccinations are both important factors in preventing new cases and 367 progression to severe disease. A critical aspect for effective scheduling of vaccinations is 368 understanding how long immunity persists following infection in various age groups. Our study 369 demonstrated that infants/young children produce a significantly more durable antibody response 370 to SARS-CoV-2 S antigens following infection as compared to adults, a response that correlates 371 with extended neutralization, which may have implications for scheduling of vaccination and 372 boosters. In addition, we found that natural infection confers a similar breadth of antibody 373 repertoire in these disparate age groups, indicating a need for further study on the effect of 374 boosters for prevention of continuously evolving variants.

375

376 Limitations of the study

377 The major limitation of this study was the small cohort size which did not allow us to study the 378 sex related effects to the SARS-CoV-2 infection induced immune response in infants/young 379 children. Several reports have described notable differences in the immune response to COVID-380 19 between males and females (42-45). Thus, it is possible that this could have impacted our 381 findings. However, while not fully powered to address this, we found no difference in the 382 immune response to SARS-CoV-2 infection in infants/young children comparing males and 383 females (data not shown). Future studies with larger number of infants/young children in the 384 study cohort would be needed to better address this question. In addition, while our study 385 compared an immune response to infection in infants/young children and adults, these donors 386 were infected at different times during the pandemic most likely with corresponding main 387 circulating viral variants. While it would have been interesting to compare the infants/young 388 children and adults matched with respect to time of infection, we did not have the longitudinally 389 followed matched donors to evaluate this. However, a similar breadth of antibody repertoire 390 against VOCs in infants/young children and adults highlight the relevance of our findings. 391

392 Methods

393

394 Participant sample collection

The enrolled infants/young children at Cincinnati children's hospital were part of a larger study of influenza infection and vaccination in early life. The study population included infants/young children who were followed since birth with weekly nasal swabs and twice weekly symptom surveys to diagnose the respiratory infections and describe clinical presentations, respectively.

399	The blood and saliva samples were collected from these donors prior to and acutely after
400	influenza vaccination or infection and SARS-CoV-2 vaccination or infection with longitudinally
401	collected convalescent blood samples following these events. The Atlanta study population
402	included adult volunteers over the age 18 who were diagnosed with COVID-19 by a
403	commercially available SARS-CoV-2 PCR test. Informed consent was obtained from all
404	participants prior to conduct of study procedures. The participants provided a medical history of
405	co-morbidities, presentation of SARS-CoV-2 infection onset and disease course. The serial
406	peripheral blood samples were collected starting approximately 30 days after SARS-CoV-2
407	infection and thereafter at 3, 6, and 9 months. The participants were excluded if they were
408	immunocompromised, HIV positive, had active hepatitis B or C virus infection, used
409	immunosuppressive drugs for 2 weeks or more in the preceding 3 months, received blood
410	products or immunoglobulin 42 days prior to enrollment, received convalescent COVID-19
411	plasma, or were pregnant or breastfeeding.

412

413 Viruses and cell lines

414 VeroE6-TMPRSS2 cells were cultured as described previously (46) and used to propagate all

415 virus stocks. nCOV/USA_WA1\2020 (WA1), closely resembling the original Wuhan strain was

416 propagated from an infectious SARS-CoV-2 clone as described previously (47). The B.1.351

417 variant isolate was kindly provided by Dr. Andy Pekosz (John Hopkins University, Baltimore,

418 MD), was propagated once to generate a working stock (46). hCOV-19/USA/PHC658/2021

419 referred to as B.1.617.2 variant) was derived from nasal swab collected in May 2021 (48).

420 EPI_ISL_7171744 (BA.1) variant was propagated once to generate the working stock (49). All

421 variants were plaque purified on VeroE6-TMPRSS2 cells and propagated once in a 12-well plate

422 of confluent VeroE6-TMPRSS2 cells followed by expansion of the working stock in T175 flasks
423 on confluent VeroE6-TMPRSS2 cells. All viruses used in this study were deep sequenced and
424 confirmed as previously described (48).

425

426 Multiplex electrochemiluminescence (ECLIA) Immunoassay

427 The levels of IgG, and IgA antibodies were measured using the multiplex plates by Mesoscale

428 Discovery (MSD), following manufacturer's instructions. The V-PLEX Coronavirus Plate 1

429 (K15362U) were used to analyze the binding antibody responses against WT SARS-CoV-2 and

430 other human coronaviruses, while V-PLEX SARS-CoV-2 panel 24 (K15575U) and panel 26

431 (K15593U) were used to assess the binding antibody responses to additional VOC-derived spike

432 and RBD respectively. Briefly the plates were first blocked using the 5 % solution of Bovine

433 Serum Albumin (BSA) in 1X PBS and incubated at room temperature with shaking at 700 RPM

434 for at least 30 min. Following incubation, the plates were washed three times using 1X DPBS/

435 0.05 % Tween. The serum samples, diluted 1:5000 (for IgG), and 1:1000 (for IgA, and IgM),

436 were added and the plates were incubated at room temperature with shaking at 700 RPM for 2 h.

437 Following a wash, sulfo-tag anti-human detection antibody (IgG, IgA, IgM, IgG1 Fc, IgG2, Fc,

438 IgG3 Fc, or IgG4 Fc) were added, and the plates were incubated at room temperature with

439 shaking at 700 RPM for 1 h. After the subsequent wash, 150 uL/well of MSD Gold Read Buffer

440 B was added to the plates and the plates were read immediately on the MSD instrument to

441 measure the light intensity. The levels of the antibodies are reported as the arbitrary units/ mL

442 (AU/mL) or μ g/mL based on the normalization of the standard curve.

443

444

445 Focus reduction neutralization assay

- 446 The FRNT assays were performed as described previously (46, 48, 50). Briefly, the plasma
- 447 samples were diluted 3-fold in eight serial dilution in DMEM in duplicates, with an initial
- 448 dilution of 1:10 in a total volume of 60 µL, followed by incubation with equal volume of
- 449 respective SARS-CoV-2 variant. The antibody-virus mixture was then added to VeroE6-
- 450 TMPRSS2 cells. After incubation, the antibody-virus mixture was removed and pre-warmed 0.85
- 451 % methylcellulose overlay was added to each well. After removal of the overlay, the cells were
- 452 fixed with 2 % paraformaldehyde in PBS. Following fixation, permeabilization buffer (0.1 %
- 453 BSA, Saponin in PBS) was added to the permeabilized cells. The cells were incubated with an
- 454 anti-SARS-CoV spike primary antibody directly conjugated to Alexafluor-647 (CR3022-

455 AF647). The foci were visualized on an ELISpot reader (CTL).

456

457 Statistical analysis

458 Mixed effects exponential and power law models implemented in Monolix (Monolix, Lixoft) 459 were used to analyze the waning of the antibody response (day 30 to day 500 in infants/young 460 children and day 30 to day 350 in adult donors). The exponential and power law models were formulated as ordinary differential equations, $\frac{dAb}{dt} = -k \cdot Ab$ and $\frac{dAb}{dt} = -\frac{k}{t} \cdot Ab$, respectively, 461 462 with antibody at day 30 lognormally distributed and decay rate k normally distributed and with 463 lognormal multiplicative error. The data were analyzed using GraphPad Prism 9.5.0. The 464 antibody neutralization titers were quantified by counting number of foci for each sample using 465 the Viridot program. The neutralization titers were calculated as [1 – (average number of foci in 466 wells incubated with patient serum) ÷ (average number of foci in wells incubated with control 467 serum)]. The correlation analyses to determine coefficient of determination (R^2) , and

468	significance were performed by log transforming the binding and neutralization titers followed				
469	by simple linear regression. The comparisons between groups were performed using unpaired				
470	two-tailed t-test.				
471					
472	Study approval				
473	The longitudinal IMPRINT influenza cohort study at Cincinnati Children's Hospital Medical				
474	Center (Cincinnati, OH) and COVID-19 longitudinal cohort study at Emory University (Atlanta,				
475	Georgia) began after receiving the Institutional Review Board approvals (IRB 2019-0629,				
476	IRB00022371 respectively).				
477					
478	Funding Details				
479	This work was supported in part by grants U01AI144673-02, 3U19AI057266-17S2, and				
480	U54CA260563 from the National Institute of Allergy and Infectious Diseases (NIAID), National				
481	Institutes of Health (NIH), and by the Oliver S. and Jennie R. Donaldson Charitable Trust,				
482	Emory Executive Vice President for Health Affairs Synergy Fund award, the Georgia Research				
483	Alliance, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and				
484	Children's Healthcare of Atlanta, the Emory-UGA Center of Excellence for Influenza Research				
485	and Surveillance (Atlanta, GA USA), and a Woodruff Health Sciences Center 2020 COVID-19				
486	CURE Award.				
487					
488	Author Contribution				
489	D.J. performed data acquisition, data curation and analysis, data visualization, and writing the				

490 manuscript. L.E.N and V.Z. contributed to data curation and analysis, data visualization, writing

491	review and editing. A.M., K.M., and S.L contributed to investigation, data curation and analysis.
492	A.R.B. and K.S. provided clinical support, contributed to patient recruitment and clinical data
493	curation. G.M. and C.N. contributed to patient sample collection and paper review. R.A., E.J.A.,
494	M.A.S., M.S.S., and J.W. contributed to the conception and design of the study, writing and
495	editing of the manuscript, and obtaining study funding. All authors have read and accepted the
496	manuscript.

497

498 **Declaration of Interest**

499 MSS has served as an advisor for Ocugen and Moderna. E.J.A. has consulted for Pfizer, Sanofi 500 Pasteur, Janssen, and Medscape, and his institution receives funds to conduct clinical research 501 unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sonfi-502 Pasteur, Janssen, and Micron. He also serves on data and safety monitoring boards for Kentucky 503 BioProcessing, Inc., and Sanofi Pasteur. His institution has also received funding from NIH to 504 conduct clinical trials of Moderna and Janssen COVID-19 vaccines. M.A.S. received funding 505 from CDC, Pfizer, Merck and Cepheid to study immune response to respiratory virus infections 506 and vaccinations.

507

508 Acknowledgements

509 We thank the participants and parents of infant donors for volunteering their time and efforts to

510 participate in this study. We also thank Christina Rostad and Sanjeev Kumar for critically

511 reviewing the manuscript. The graphical abstract was created using Biorender.com.

512 References

- Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Consortium C-GU, et al.
 SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nat Rev Microbiol.* 2023;21(3):162-77.
- 5162.Zhou Y, Zhi H, and Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune517escape, and vaccine effectivity. Journal of Medical Virology. 2023;95(1):e28138.
- 5183.Townsend JP, Hassler HB, Sah P, Galvani AP, and Dornburg A. The durability of natural519infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc520Natl Acad Sci U S A. 2022;119(31):e2204336119.
- Mantus G, Nyhoff LE, Edara VV, Zarnitsyna VI, Ciric CR, Flowers MW, et al. Pre-existing
 SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral
 response to SARS-CoV-2 vaccination. *Cell Rep Med.* 2022;3(4):100603.
- 5245.Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal525analysis shows durable and broad immune memory after SARS-CoV-2 infection with526persisting antibody responses and memory B and T cells. Cell Rep Med.5272021;2(7):100354.
- 6. Gilboa M, Regev-Yochay G, Mandelboim M, Indenbaum V, Asraf K, Fluss R, et al.
 529 Durability of Immune Response After COVID-19 Booster Vaccination and Association
 530 With COVID-19 Omicron Infection. JAMA Netw Open. 2022;5(9):e2231778.
- 5317.Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung PK, et al. Reduced532Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines533Among Older Adults. J Infect Dis. 2022;225(7):1129-40.
- 5348.Suthar MS, Arunachalam PS, Hu M, Reis N, Trisal M, Raeber O, et al. Durability of535immune responses to the BNT162b2 mRNA vaccine. *Med.* 2022;3(1):25-7.
- 5369.Di Chiara C, Cantarutti A, Costenaro P, Dona D, Bonfante F, Cosma C, et al. Long-term537Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild538Infection. JAMA Netw Open. 2022;5(7):e2221616.
- 53910.Gupta SL, Mantus G, Manning KE, Ellis M, Patel M, Ciric CR, et al. Loss of Pfizer540(BNT162b2) vaccine-induced antibody responses against the SARS-CoV-2 Omicron541variant in adolescents and adults. Journal of virology. 2022;96(17):e00582-22.
- 542 11. Goenka A, Halliday A, Gregorova M, Milodowski E, Thomas A, Williamson MK, et al.
 543 Young infants exhibit robust functional antibody responses and restrained IFN-gamma
 544 production to SARS-CoV-2. *Cell Rep Med.* 2021;2(7):100327.
- 545 12. O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al.
 546 Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature.*547 2021;590(7844):140-5.
- Trevisanuto D, Cavallin F, Cavicchiolo ME, Borellini M, Calgaro S, and Baraldi E.
 Coronavirus infection in neonates: a systematic review. *Arch Dis Child Fetal Neonatal Ed.*2021;106(3):330-5.
- 55114.Simon AK, Hollander GA, and McMichael A. Evolution of the immune system in humans552from infancy to old age. *Proc Biol Sci.* 2015;282(1821):20143085.

553	15.	Sempowski GD, Saunders KO, Acharya P, Wiehe KJ, and Haynes BF. Pandemic
554		Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell.
555		2020;181(7):1458-63.
556	16.	Noval MG. Kaczmarek ME. Koide A. Rodriguez-Rodriguez BA. Louie P. Tada T. et al.
557	-	Antibody isotype diversity against SARS-CoV-2 is associated with differential serum
558		neutralization capacities. <i>Sci Rep.</i> 2021:11(1):5538.
559	17.	Gallais E. Gantner P. Bruel T. Velay A. Planas D. Wendling MI. et al. Evolution of antibody
560	-/.	responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
561		FBioMedicine 2021.71.103561
562	18	Capetti AF Borgonovo F Mileto D Gagliardi G Mariani C Luno A et al One-vear
563	10.	durability of anti-spike lgG to SARS-CoV-2. Preliminary data from the anticrown
564		prospective observational study one year durability of COVID-19 anti-spike IgG Journal
565		of Infection 2021/83(2)/237-79
566	19	Elores-Vega VR Monroy-Molina IV limenez-Hernandez LE Torres AG Santos-Preciado
567	19.	IL and Rosales-Reves R SARS-CoV-2: Evolution and Emergence of New Viral Variants
568		$V_{irus \rho s} = 2022 \cdot 1 \Lambda(\Lambda)$
560	20	Duang D. Alpha. Bata. Dalta. Camma: W/hat's important to know about SAPS. CoV/2
570	20.	variants of concern? CMAL 2021:103(27):E1050-E60
570	21	Bates TA Weinstein IB Leier HC Messer WB and Tafesse EG Cross-reactivity of SARS-
572	21.	CoV structural protein antibodies against $SARS_CoV_2$ Coll reports 2021:34(7):108737
572	22	Vates II. Ehrbar DI. Hunt DT. Girardin RC. Dunuis AP. and Payne AF. et al. Serological
573	22.	analysis royaals an imbalanced IgG subclass composition associated with COVID-19
575		disease severity Cell Ren Med 2021-2(7)-100329
576	23	Abayasingam A Balashandran H Aganiou D Hammoud M Bodrigo C Keoshkerian E et
570	25.	Abayasingan A, balachandran H, Agaplou D, Hammoud W, Koungo C, Reosinkerian L, et $a_1 \ Long torm porsistonce of PBD(+) memory B colls oncoding neutralizing antibodies in$
578		SAPS CoV 2 infoction Call Pan Mad 2021-2(4):100228
570	24	Wheatley AK June IA Wang II Solva KI Roynaldi A Tan HY at al Evolution of immuno
580	24.	responses to SAPS CoV/2 in mild moderate COV/D-19. Nat Commun. 2021:12(1):1162
581	25	Soow Graham C Marrick B. Acors S. Diskaring S. Stool KIA. at al. Longitudinal
501	25.	seew J, Granani C, Merrick B, Acors S, Pickering S, Steer NJA, et al. Longituunia
502 502		following SARS CoV 2 infortion in humans. Nat Microbiol. 2020;E(12):1E08.607
505	26	Addetia A Crawford KIL Diagons A Zhu LL Davebaudhum D Lluang M L at al
505	20.	Addetta A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huding M-L, et al.
505		fisher weed outbrook with a high attack rate. Journal of aliginal migrahiology
380 597		nshery vessel outbreak with a high attack rate. <i>Journal of clinical microbiology</i> .
38/ 500	27	2020;58(11):e02107-20.
200 500	27.	meleo it count. Front (mmuno), 2022:12:1021024
500	20	makes it count. Front Immunol. 2022;13:1031924.
590 501	28.	Huang Q, Zeng J, and Yan J. COVID-19 MRNA vaccines. J Genet Genomics.
502	20	2021;48(2):107-14.
592 502	29.	Hogan MJ, and Pardi N. MRNA vaccines in the COVID-19 Pandemic and Beyond. Annu
595 504	20	Kev Wea. 2022;/3:1/-39.
394 505	30.	Suthar IVIS, Zimmerman IVIG, Kauriman KC, Mantus G, Linderman SL, Hudson WH, et al.
393 507		Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep
396		Niea. 2020;1(3):100040.

597	31.	Andualem H, Kiros M, Getu S, and Hailemichael W. Immunoglobulin G2 Antibody as a		
598		Potential Target for COVID-19 Vaccine. Immunotargets Ther. 2020;9:143-9.		
599	32.	Lu LL, Suscovich TJ, Fortune SM, and Alter G. Beyond binding: antibody effector		
600		functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46-61.		
601	33.	Fraley E, LeMaster C, Banerjee D, Khanal S, Selvarangan R, and Bradley T. Cross-reactiv		
602		antibody immunity against SARS-CoV-2 in children and adults. <i>Cell Mol Immunol</i> .		
603		2021;18(7):1826-8.		
604	34.	Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal		
605		iuman coronavirus antibodies are boosted upon SARS-CoV-2 infection but not		
606		associated with protection. <i>Cell.</i> 2021;184(7):1858-64 e10.		
607	35.	Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J, et al. Cross-reactive antibody against		
608		human coronavirus OC43 spike protein correlates with disease severity in COVID-19		
609		patients: a retrospective study. <i>Emerg Microbes Infect</i> . 2021:10(1):664-76.		
610	36.	Renk H, Dulovic A, Seidel A, Becker M, Fabricius D, Zernickel M, et al. Robust and		
611		durable serological response following pediatric SARS-CoV-2 infection. <i>Nat Commun.</i>		
612		2022:13(1):128.		
613	37.	Wong LSY, Loo EXL, Huang CH, Yap GC, Tay MJY, Chua RXY, et al. Early seasonal		
614		coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies. J		
615		Infect. 2023:86(1):e10-e2.		
616	38.	Stamatatos L. Czartoski J. Wan Y-H. Homad LJ. Rubin V. Glantz H. et al. mRNA		
617		vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2		
618		infection. <i>Science</i> . 2021;372(6549):1413-8.		
619	39.	Zou J, Xia H, Xie X, Kurhade C, Machado RR, Weaver SC, et al. Neutralization against		
620		Omicron SARS-CoV-2 from previous non-Omicron infection. <i>Nature communications.</i>		
621		2022;13(1):852.		
622	40.	Goga A, Bekker LG, Garrett N, Reddy T, Yende-Zuma N, Fairall L, et al. Breakthrough		
623		SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa.		
624		Lancet. 2022;400(10348):269-71.		
625	41.	Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. Neutralization against		
626		BA. 2.75. 2, BQ. 1.1, and XBB from mRNA Bivalent Booster. <i>New England Journal of</i>		
627		Medicine. 2023;388(2):183-5.		
628	42.	Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in		
629		immune responses that underlie COVID-19 disease outcomes. Nature.		
630		2020;588(7837):315-20.		
631	43.	Scully EP, Haverfield J, Ursin RL, Tannenbaum C, and Klein SL. Considering how biological		
632		sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol.		
633		2020;20(7):442-7.		
634	44.	Pradhan A, and Olsson PE. Sex differences in severity and mortality from COVID-19: are		
635		males more vulnerable? <i>Biol Sex Differ</i> . 2020;11(1):53.		
636	45.	Gomez JMD, Du-Fay-de-Lavallaz JM, Fugar S, Sarau A, Simmons JA, Clark B, et al. Sex		
637		differences in COVID-19 hospitalization and mortality. Journal of Women's health.		
638		2021;30(5):646-53.		

639 640 641	46.	Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host Microbe</i> . 2021;29(4):516-21 e3.
642	47.	Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An Infectious
644 645 646	48.	Edara V-V, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B. 1.617 variants. <i>New England Journal of Medicine</i> . 2021;385(7):664-6.
647 648 649	49.	Kumar S, Patel A, Lai L, Chakravarthy C, Valanparambil R, Reddy ES, et al. Structural insights for neutralization of Omicron variants BA. 1, BA. 2, BA. 4, and BA. 5 by a broadly neutralizing SARS-CoV-2 antibody. <i>Science Advances.</i> 2022;8(40):eadd2032.
650 651 652 653	50.	Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, et al. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS- CoV-2 Neutralizing Antibodies. <i>Curr Protoc Immunol.</i> 2020;131(1):e116.
654		
655		
656		
657		
658		
659		
660		
661		
662		
663		
664		
665		
666		
667		
008		

Table 1: Cohort demographics

		Infants/young children	Adults
Sex	Females (%)	13 (57%)	10 (53%)
	Males (%)	10 (43%)	9 (47%)
Median age (range)		249 d (40 – 1441 d)	54 y (20 – 77 y)
Samples collected		February 2020 – April 2022	May 2020 – March 2021
COVID-19 infection		April 2020 – January 2022	March 2020 – April 2020
Patients requiring		None (0 %)	3 (16 %)
hospitalization			
Severe symptoms		None (0 %)	None (0 %)

683



685 Figure 1: Infants/young children generate durable antibody responses to SARS-CoV-2

686 **antigens following infection.** IgG (A - C), and IgA (D - F) antibodies reactive to SARS-CoV-2

687 spike (A, D); spike receptor binding domain (RBD) (B, E); and the spike N-terminal domain

688 (NTD) (C, F) were measured in duplicate by an electrochemiluminescent multiplex

689 immunoassay and reported as arbitrary units per ml (AU/mL) as normalized by a standard curve.

690 Longitudinal antibody titers of SARS-Co-2 infected infants/young children (n = 23) are plotted 691 over days post positive PCR result. The dotted line represents the limit of detection, defined as

- 692 the mean value pre-infection + 3SD.
- 693

694

695







- 699 IgG antibodies reactive to the (A) previous epidemic coronaviruses, MERS-CoV and SARS-
- 700 CoV-1 spike protein, and (B) common human beta-coronaviruses, HKU1 and OC43 spike
- 701 protein were measured in duplicate by an electrochemiluminescent multiplex immunoassay and
- 702 reported as arbitrary units per ml (AU/mL) as normalized by a standard curve. Longitudinal
- 703 antibody titers of SARS-CoV-2 infected infants/young children (n = 23) are plotted over days
- since the positive PCR result. (C) Pre- SARS-CoV-2 infection IgG binding antibody titers 704 705
- against the spike proteins of currently circulating human beta coronaviruses, HKU1 and OC43,
- 706 showed no correlation with the convalescent titers against SARS-CoV-2 spike in infants/young
- 707 children. Coefficient of determination (R^2) , and significance were determined by linear 708 regression analysis.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.10.23288360; this version posted April 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 3: Durability of SARS-CoV-2 spike- and nucleocapsid-binding antibody responses
 in infants/young children and adults.

712 IgG antibodies reactive to SARS-CoV-2 spike (A, E); spike RBD (B, F); spike NTD (C, G); and

- 713 nucleocapsid (D, H) were measured in duplicate by an electrochemiluminescent multiplex
- 714 immunoassay in infants/young children (A D), and adult (E H) donors and reported as
- arbitrary units per ml (AU/mL) as normalized by a standard curve. The half-lives and decay
- 716 curves of the IgG antibodies estimated by the exponential model are shown in red; and the half-
- 717 lives and decay curves of IgG antibodies estimated by the power law model (at day 150) are
- shown in blue.
- 719

- 721
- 722
- . __
- 723
- 724
- 725
- 726
- 727
- 720
- 728



729

730 Figure 4: Anti-spike IgG subclass distribution in infants/young children and adults.

731 The concentration of anti-spike IgG subclasses was measured at an early (30 - 140 days post)

infection, red) and late (250 – 375 days post infection, blue) time points. (A) Early and late time

point samples from the infant and adult donors chosen to assess the antibody subclass

- distribution. (B) Concentration (ug/mL) of anti-spike IgG1, IgG2, IgG3 and IgG4 antibodies at
- early and late time points in infants and adults. Statistics were calculated using two-tailed Mann-
- 736 Whitney test. ns not significant, *p<0.05, **p<0.01.
- 737
- 738 739
- 740
- 741



Figure 5: Neutralizing antibody responses against WT SARS-CoV-2 spike in infants/young children and adults. (A) Neutralizing antibody titers against WT SARS-CoV-2 at early and late time points in infants and adult donors. (B) SARS-CoV-2 spike and RBD reactive IgG (AU/mL) levels correlated with the neutralization titers at matched timepoints for infant and adult donors. The dotted line (A) represents the limit of detection at 1/20. The comparison between groups were performed using unpaired two-tailed t-test (A). The correlation analyses were performed using simple linear regression and coefficient of determination (R^2) and significance were determined (B). ns – not significant, p<0.05.



Figure 6: IgG binding and neutralizing antibody titers against WT, Beta, Delta and
Omicron (BA.1) SARS-CoV-2 RBD in infant and adult donors. Infants exhibit similar
breadth against VOCs as adults. (A) IgG binding to RBD and (B) neutralizing antibody titers
(FRNT50) were analyzed against a panel of VOCs including WT, beta, delta and omicron
(BA.1). The dotted line represents the limit of detection at 1/20 (B). Both infants' and adults'
plasma samples were compared at early and late time points and fold change was calculated as
variant binding (A) or neutralization (B) compared to WT.

